| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS42001432 | EBV | ENSG00000196277.17 | protein_coding | GRM7 | No | No | 2917 | B9EGG9 Q14831 |
| TVIS42001404 | EBV | ENSG00000196277.17 | protein_coding | GRM7 | No | No | 2917 | B9EGG9 Q14831 |
| TVIS10000107 | HBV | ENSG00000196277.17 | protein_coding | GRM7 | No | No | 2917 | B9EGG9 Q14831 |
| TVIS10015161 | HBV | ENSG00000196277.17 | protein_coding | GRM7 | No | No | 2917 | B9EGG9 Q14831 |
| TVIS10000108 | HBV | ENSG00000196277.17 | protein_coding | GRM7 | No | No | 2917 | B9EGG9 Q14831 |
| TVIS10002071 | HBV | ENSG00000196277.17 | protein_coding | GRM7 | No | No | 2917 | B9EGG9 Q14831 |
| TVIS10006446 | HBV | ENSG00000196277.17 | protein_coding | GRM7 | No | No | 2917 | B9EGG9 Q14831 |
| TVIS10029229 | HBV | ENSG00000196277.17 | protein_coding | GRM7 | No | No | 2917 | B9EGG9 Q14831 |
| TVIS10032740 | HBV | ENSG00000196277.17 | protein_coding | GRM7 | No | No | 2917 | B9EGG9 Q14831 |
| TVIS10029230 | HBV | ENSG00000196277.17 | protein_coding | GRM7 | No | No | 2917 | B9EGG9 Q14831 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | GRM7 |
|---|---|
| DrugBank ID | DB00142 |
| Drug Name | Glutamic acid |
| Target ID | BE0000834 |
| UniProt ID | Q14831 |
| Regulation Type | |
| PubMed IDs | 17360958 |
| Citations | Suzuki G, Kimura T, Satow A, Kaneko N, Fukuda J, Hikichi H, Sakai N, Maehara S, Kawagoe-Takaki H, Hata M, Azuma T, Ito S, Kawamoto H, Ohta H: Pharmacological characterization of a new, orally active and potent allosteric metabotropic glutamate receptor 1 antagonist, 4-[1-(2-fluoropyridin-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl- 3,6-dihydropyridine-1(2H)-carboxamide (FTIDC). J Pharmacol Exp Ther. 2007 Jun;321(3):1144-53. Epub 2007 Mar 14. |
| Groups | Approved; Nutraceutical |
| Direct Classification | Glutamic acid and derivatives |
| SMILES | N[C@@H](CCC(O)=O)C(O)=O |
| Pathways | Histidinemia; Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency); 3-Methylglutaconic Aciduria Type I; beta-Ketothiolase Deficiency; Purine Nucleoside Phosphorylase Deficiency; Tyrosine Metabolism; Ketoprofen Action Pathway; Glutamate Metabolism; Argininosuccinic Aciduria; Salla Disease/Infantile Sialic Acid Storage Disease; Tyrosinemia Type I; Hyperinsulinism-Hyperammonemia Syndrome; 2-Methyl-3-hydroxybutryl-CoA Dehydrogenase Deficiency; Glutaric Aciduria Type I; Propanoate Metabolism; Celecoxib Action Pathway; Glycine and Serine Metabolism; Suprofen Action Pathway; Indomethacin Action Pathway; Carbamoyl Phosphate Synthetase Deficiency; Sialuria or French Type Sialuria; Ibuprofen Action Pathway; Saccharopinuria/Hyperlysinemia II; Histidine Metabolism; Arginine and Proline Metabolism; Purine Metabolism; Diflunisal Action Pathway; Etodolac Action Pathway; Ammonia Recycling |
| PharmGKB | PA449776 |
| ChEMBL | CHEMBL575060 |
